We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $20.14 · 7 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology? - simplywall.st
Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology? simplywall.st
Jupiter Asset Management Ltd. Acquires 91,683 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Jupiter Asset Management Ltd. Acquires 91,683 Shares of Adaptive Biotechnologies Corporation $ADPT MarketBeat
Liquidity Mapping Around (ADPT) Price Events - Stock Traders Daily
Liquidity Mapping Around (ADPT) Price Events Stock Traders Daily
Adaptive Biotechnologies Hits Day High with 9.75% Surge in Stock Price - Markets Mojo
Adaptive Biotechnologies Hits Day High with 9.75% Surge in Stock Price Markets Mojo
Adaptive Biotechnologies Corporation Reports New Data Reinforcing Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research - marketscreener.com
Adaptive Biotechnologies Corporation Reports New Data Reinforcing Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research marketscreener.com
Adaptive Biotechnologies Announces Extensive Presence at ASCO and EHA Conferences Showcasing clonoSEQ Test for MRD Assessment - Quiver Quantitative
Adaptive Biotechnologies Announces Extensive Presence at ASCO and EHA Conferences Showcasing clonoSEQ Test for MRD Assessment Quiver Quantitative
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $-0.14 | — | — | $65.69M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.2 | — | — | $52.44M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.86 | — | — | $131.5M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.64 | — | — | $85.06M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 05. 07. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 07. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 05. 06. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 06. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 02. 07. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.